[HTML][HTML] … antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: an open-label, controlled, sequential study
S Weisshaar, B Litschauer, S Bucher, M Riesenhuber… - Medicine, 2016 - journals.lww.com
… in particular with newer antithrombotic medicines. We have … studied if dual or triple combination
of antithrombotic agents exert similar effects on coagulation activation in an in vivo model …
of antithrombotic agents exert similar effects on coagulation activation in an in vivo model …
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber
M Wolzt, G Gouya, S Kapiotis, M Becka, W Mueck… - Thrombosis …, 2013 - Elsevier
… sequence, subject (sequence), period and, treatment effects … , studies investigating the direct
factor Xa inhibitor apixaban (… DEEM) in addition to antiplatelet therapy in patients with ACS …
factor Xa inhibitor apixaban (… DEEM) in addition to antiplatelet therapy in patients with ACS …
[HTML][HTML] Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens
J Martinez-Sanchez, L Castrillo, D Jerez… - Scientific Reports, 2023 - nature.com
… from participants were spiked ex vivo with apixaban 0 (APIX0), … the antiplatelet effects of
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …
Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study
K Balasubramaniam, G Viswanathan… - Thrombosis and …, 2014 - thieme-connect.com
… sponse ex vivo, using the Badimon perfusion chamber system … Thrombus and antiplatelet
therapy in type 2 diabetes mellitus… Xa inhibitor apixaban for symptomatic deep vein thrombosis. …
therapy in type 2 diabetes mellitus… Xa inhibitor apixaban for symptomatic deep vein thrombosis. …
Novel approaches to antiplatelet therapy
P Gresele, S Momi - Biochemical Pharmacology, 2022 - Elsevier
… and has two tyrosines in a conserved sequence known as an … vivo, alone and in combination
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications
… Antithrombotic therapy plays a key role in the treatment of … a prospective, open-label,
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …
[HTML][HTML] Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis
… oral anticoagulant and antiplatelet therapy. Any combination … Thrombus targeting was
confirmed using IVIS in vivo imaging … TAP was designed according to published sequence …
confirmed using IVIS in vivo imaging … TAP was designed according to published sequence …
The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism
G Escolar, M Diaz-Ricart… - Expert Opinion on …, 2014 - Taylor & Francis
… antithrombotic therapies in the prophylaxis and treatment of … an open-label, randomized,
non-treatment and active-controlled … (dabigatran, rivaroxaban and apixaban) being approved or …
non-treatment and active-controlled … (dabigatran, rivaroxaban and apixaban) being approved or …
[HTML][HTML] Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - thieme-connect.com
… for thrombus formation and targets for oral antithrombotic … effects in in vitro assays and
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
A Szczeklik, J Musiał, A Undas, P Gajewski… - Journal of the American …, 1999 - jacc.org
… Volumes of consecutive blood samples were also recorded. … venous blood in an ex vivo
superfusion chamber. DiGarbo et … in the ex vivo model used in the present study, because …
superfusion chamber. DiGarbo et … in the ex vivo model used in the present study, because …